Zydus Lifesciences Hits Record High! US FDA Nod Boosts Stock 4.61% | Stock Market News
Zydus Lifesciences blasts through the roof, hitting a 52-week high after the US FDA greenlights a Phase II trial for its Parkinson's disease drug ZYIL1! This potential blockbuster medication targets a $2 billion market, setting Zydus on fire.
Written By: Zee Business Video Team